MAFIP is a tumor suppressor in cervical cancer that inhibits activation of the nuclear factor-kappa B pathway

Cancer Science

Volumn 102, Issue 11, 2011, Pages 2043-2050

  Li, Yang ^a,b   Yu, Yao ^a   Zhang, Yan ^c   Zhou, Yufei ^a   Li, Chao ^a   Zhu, Jianbing ^a   Yuan, Hanying ^a   Lu, Hong ^a,d  

^a FUDAN UNIVERSITY   (China)

^b ANHUI MEDICAL UNIVERSITY   (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

^d FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ACTIN; I KAPPA B KINASE; I KAPPA B KINASE ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN MAFIP; PROTEIN P21; PROTEIN P53; SMALL INTERFERING RNA; SYNAPTOTAGMIN I; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; FEMALE; GENE INACTIVATION; GENE INDUCTION; GENE OVEREXPRESSION; HELA CELL; HUMAN; HUMAN CELL; IN VIVO STUDY; MAFIP GENE; MOUSE; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; NUDE MOUSE; ONCOGENE C MYC; PRIORITY JOURNAL; PROTEIN DEGRADATION; UTERINE CERVIX CANCER;

ANIMALS; CARRIER PROTEINS; CERVICAL INTRAEPITHELIAL NEOPLASIA; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HELA CELLS; HUMANS; I-KAPPA B KINASE; I-KAPPA B PROTEINS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM PROTEINS; NF-KAPPA B; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEINS; UTERINE CERVICAL NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80055025466     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2011.02061.x     Document Type: Article

References (54)

1. Kahn JA. HPV vaccination for the prevention of cervical intraepithelial neoplasia. N Engl J Med 2009; 361: 271-8.
2. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002; 55: 244-65.
3. Wolf JK, Ramirez PT. The molecular biology of cervical cancer. Cancer Invest 2001; 19: 621-9.
4. Lazo PA. The molecular genetics of cervical carcinoma. Br J Cancer 1999; 80: 2008-18.
5. Lin LF, Chuang CH, Li CF et al. ZBRK1 acts as a metastatic suppressor by directly regulating MMP9 in cervical cancer. Cancer Res 2010; 70: 192-201.
6. Liu CY, Chao TK, Su PH et al. Characterization of LMX-1A as a metastasis suppressor in cervical cancer. J Pathol 2009; 219: 222-31.
7. Rho SB, Park YG, Park K, Lee SH, Lee JH. A novel cervical cancer suppressor 3 (CCS-3) interacts with the BTB domain of PLZF and inhibits the cell growth by inducing apoptosis. FEBS Lett 2006; 580: 4073-80.
8. Hasina R, Pontier AL, Fekete MJ et al. NOL7 is a nucleolar candidate tumor suppressor gene in cervical cancer that modulates the angiogenic phenotype. Oncogene 2006; 25: 588-98.
9. Lee EJ, Jo M, Rho SB et al. Dkk3, downregulated in cervical cancer, functions as a negative regulator of beta-catenin. Int J Cancer 2009; 124: 287-97.
10. Aggarwal B. Nuclear factor-κB the enemy within. Cancer Cell 2004; 6: 203-8.
11. Ahn KS, Aggarwal BB. Transcription factor NF-kappaB: a sensor for smoke and stress signals. Ann N Y Acad Sci 2005; 1056: 218-33.
12. Lee C, Jeon Y, Kim S, Song Y. NF-κB as a potential molecular target for cancer therapy. Biofactors 2007; 29: 19-35.
13. Karin M. How NF-kappaB is activated: the role of the IkappaB kinase (IKK) complex. Oncogene 1999; 18: 6867.
14. Delhase M, Hayakawa M, Chen Y, Karin M. Positive and negative regulation of IκB kinase activity through IKKβ subunit phosphorylation. Science 1999; 284: 309.
15. Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-κB activity. Annu Rev Immunol 2000; 18: 621-63.
16. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2002; 2: 420-30.
17. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006; 441: 431-6.
18. Ramdass B, Maliekal T, Lakshmi S et al. Coexpression of Notch1 and NF-κB signaling pathway components in human cervical cancer progression. Gynecol Oncol 2007; 104: 352-61.
19. Nair A, Venkatraman M, Maliekal T, Nair B, Karunagaran D. NF-κB is constitutively activated in high-grade squamous intraepithelial lesions and squamous cell carcinomas of the human uterine cervix. Oncogene 2003; 22: 50-8.
20. Prusty B, Husain S, Das B. Constitutive activation of nuclear factor-κB: preferential homodimerization of p50 subunits in cervical carcinoma. Front Biosci 2005; 10: 1510-9.
21. Ye X, Li Y, Huang Q et al. The novel human gene MIP functions as a co-activator of hMafF. Arch Biochem Biophys 2006; 449: 87-93.
22. Ye X, Lu H, Yu Y et al. pp5644 Interacts with phosphatidylinositol-4-phosphate adaptor protein-1 associated protein-1. Mol Cell Biochem 2005; 271: 151-8.
23. Chen JQ, Li Y, Pan X et al. The fission yeast inhibitor of growth (ING) protein PNG1P functions in response to DNA damage. J Biol Chem 2010; 285: 15786.
24. Chen R, Brentnall TA, Pan S et al. Quantitative proteomics analysis reveals that proteins differentially expressed in chronic pancreatitis are also frequently involved in pancreatic cancer. Mol Cell Proteomics 2007; 6: 1331-42.
25. Wang J, Liu N, Liu Z et al. The orphan nuclear receptor Rev-erbbeta recruits Tip60 and HDAC1 to regulate apolipoprotein CIII promoter. Biochim Biophys Acta 2008; 1783: 224-36.
26. Stoler MH. The virology of cervical neoplasia: an HPV-associated malignancy. Cancer J 2003; 9: 360-7.
27. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993; 75: 805-16.
28. el-Deiry WS, Tokino T, Velculescu VE et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75: 817-25.
29. Aranha MM, Sola S, Low WC, Steer CJ, Rodrigues CM. Caspases and p53 modulate FOXO3A/Id1 signaling during mouse neural stem cell differentiation. J Cell Biochem 2009; 107: 748-58.
30. Foster BA, Coffey HA, Morin MJ, Rastinejad F. Pharmacological rescue of mutant p53 conformation and function. Science 1999; 286: 2507-10.
31. Ma S, Tang J, Feng J et al. Induction of p21 by p65 in p53 null cells treated with Doxorubicin. Biochim Biophys Acta 2008; 1783: 935-40.
32. Chen C, Edelstein LC, Gelinas C. The Rel/NF-kappaB family directly activates expression of the apoptosis inhibitor Bcl-x(L). Mol Cell Biol 2000; 20: 2687-95.
33. La Rosa FA, Pierce JW, Sonenshein GE. Differential regulation of the c-myc oncogene promoter by the NF-kappa B rel family of transcription factors. Mol Cell Biol 1994; 14: 1039-44.
34. Jones P, Baylin S. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002; 3: 415-28.
35. Prasad S, Ravindran J, Aggarwal B. NF-κB and cancer: how intimate is this relationship. Mol Cell Biochem 2010; 336: 25-37.
36. Aggarwal BB, Takada Y. Pro-apototic and anti-apoptotic effects of tumor necrosis factor in tumor cells. Role of nuclear transcription factor NF-kappaB. Cancer Treat Res 2005; 126: 103-27.
37. Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS Jr. NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 1998; 281: 1680-3.
38. Hinz M, Krappmann D, Eichten A, Heder A, Scheidereit C, Strauss M. NF-kappaB function in growth control: regulation of cyclin D1 expression and G0/G1-to-S-phase transition. Mol Cell Biol 1999; 19: 2690-8.
39. Tozawa K, Sakurada S, Kohri K, Okamoto T. Effects of anti-nuclear factor kappa B reagents in blocking adhesion of human cancer cells to vascular endothelial cells. Cancer Res 1995; 55: 4162-7.
40. van de Stolpe A, Caldenhoven E, Stade BG et al. 12-O-tetradecanoylphorbol-13-acetate- and tumor necrosis factor alpha-mediated induction of intercellular adhesion molecule-1 is inhibited by dexamethasone. Functional analysis of the human intercellular adhesion molecular-1 promoter. J Biol Chem 1994; 269: 6185-92.
41. Grandori C, Cowley SM, James LP, Eisenman RN. The Myc/Max/Mad network and the transcriptional control of cell behavior. Annu Rev Cell Dev Biol 2000; 16: 653-99.
42. Grad JM, Zeng XR, Boise LH. Regulation of Bcl-xL: a little bit of this and a little bit of STAT. Curr Opin Oncol 2000; 12: 543-9.
43. Okamoto T, Sanda T, Asamitsu K. NF-κB signaling and carcinogenesis. Curr Pharm Des 2007; 13: 447-62.
44. Webster GA, Perkins ND. Transcriptional cross talk between NF-kappa B and p53. Mol Cell Biol 1999; 19: 3485.
45. Joyce D, Albanese C, Steer J, Fu M, Bouzahzah B, Pestell RG. NF-[kappa] B and cell-cycle regulation: the cyclin connection. Cytokine Growth Factor Rev 2001; 12: 73-90.
46. Barre B, Perkins ND. A cell cycle regulatory network controlling NF-κB subunit activity and function. EMBO J 2007; 26: 4841-55.
47. Liu WK, Yen PF, Chien CY, Fann MJ, Su JY, Chou CK. The inhibitor ABIN-2 disrupts the interaction of receptor-interacting protein with the kinase subunit IKKgamma to block activation of the transcription factor NF-kappaB and potentiate apoptosis. Biochem J 2004; 378: 867-76.
48. Kim JY, Kim H, Jeun SS et al. Inhibition of NF-kappaB activation by merlin. Biochem Biophys Res Commun 2002; 296: 1295-302.
49. Deng J, Miller SA, Wang HY et al. Beta-catenin interacts with and inhibits NF-kappa B in human colon and breast cancer. Cancer Cell 2002; 2: 323-34.
50. Hong JW, Allen CE, Wu LC. Inhibition of NF-kappaB by ZAS3, a zinc-finger protein that also binds to the kappaB motif. Proc Natl Acad Sci USA 2003; 100: 12301-6.
51. Berridge MJ, Irvine RF. Inositol phosphates and cell signalling. Nature 1989; 341: 197-205.
52. Isakov N, Mally MI, Scholz W, Altman A. T-Lymphocyte activation: the role of protein kinase C and the bifurcating inositol phospholipid signal transduction pathway. Immunol Rev 1987; 95: 89-111.
53. Steffan NM, Bren GD, Frantz B, Tocci MJ, O'Neill EA, Paya CV. Regulation of IκB alpha phosphorylation by PKC- and Ca(2+)-dependent signal transduction pathways. J. Immunol. 1995; 155: 4685-91.
54. Ye X, Lu H, Huo K, Chen D. Finding a novel interacting protein of the hepatic carcinoma related gene MIP: NF-κB essential modulator (NEMO). Oncol Rep 2011; 25: 231-5.